Application of targeted next-generation sequencing in the etiological diagnosis of peritoneal dialysis-associated peritonitis: a single-center prospective cohort study.

Authors

Niya Ma, Li Pu, Zhiyun Zang, Yunyun Zhang, Ruoxi Liao, Xia Liu, Yi Tang, Zi Li

Published in

International urology and nephrology. Jun 25, 2026. Epub Jun 25, 2026.

Abstract

Accurate and rapid pathogen identification is crucial for the effective treatment of peritoneal dialysis-associated peritonitis (PDAP). Targeted next-generation sequencing (tNGS) has gained popularity for detecting infectious diseases due to its defined pathogen targeting and enhanced detection efficiency. However, its application in the etiological diagnosis of PDAD has not been fully investigated.
This prospective study enrolled 35 PDAP patients from November 2023 to January 2025. Both tNGS and traditional microbial culture (TMC) were performed in the peritoneal dialysate simultaneously, with TMC as the reference standard. Discrepant results were adjudicated by clinicians with priority given to TMC.
tNGS achieved a significantly higher pathogen detection rate (PDR) than TMC (82.9% vs. 48.6%, P = 0.008) and detected 10 polymicrobial infections, whereas TMC identified none. Beyond common pathogens, tNGS also detected rare ones, including Human herpesvirus and the Mycobacterium tuberculosis complex. tNGS also had a significantly shorter detection time than TMC (22.63 h vs. 66.37 h, P < 0.001). Among the patients with prior antibiotic exposure (54.3%), tNGS maintained a higher PDR than that of TMC (89.5% vs. 26.3%, P < 0.001).
tNGS showed a significantly higher PDR and a shorter detecting time than TMC in patients with PDAP, particularly in those with prior antibiotic exposure. Additionally, this method enables the identification of rare pathogens that are undetectable by TMC. As a complementary tool to conventional methods, combining tNGS with TMC may enable more comprehensive and rapid pathogen diagnosis, thereby improving diagnostic accuracy and patient prognosis.
This study was registered in the China Clinical Trials Registry (ChiCTR2300078924).

PMID:
42348136
Bibliographic data and abstract were imported from PubMed on 25 Jun 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.